Fig. 2 | Nature Communications

Fig. 2

From: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Fig. 2

Longitudinal multi-region HER2-positive breast cancer cohort. Pre-treatment tumor sizes were determined from the medical oncologist’s initial measurements. Post-treatment (or in P6, surgical) tumor sizes were determined from the pathologist’s report of the surgical specimen. Tumors are drawn to scale and approximate locations of the tumor blocks from which the multi-region samples are shown. TCH docetaxel/carboplatin/trastuzumab. Tumor shapes from BioRender

Back to article page